The use of ultrasound-guided fine-needle aspiration (FNA) biopsy for nonpalpable breast lesions varies considerably. This retrospective study stresses the role of breast FNA in evaluating sonographically suspicious nonpalpable breast masses using a probabilistic reporting system. One hundred and eight consecutive ultrasound-guided FNA biopsies diagnosed as positive (32), suspicious (8), atypical (11), benign (55), and unsatisfactory (2) were analyzed and correlated with 61 subsequent surgical specimens. All positive cytologies showed carcinoma on histology; suspicious cases were followed by 5 carcinomas, 2 fibroadenomas, and 1 papillary lesion. Follow-up of atypical cases included 4 carcinomas, 3 fibroadenomas, and 2 papillary lesions, while all 10 biopsies following benign cytology showed fibrocystic changes. Two cases with suspicious sonographic findings but unsatisfactory cytology had lobular carcinoma. The remainder of the benign and atypical cases were followed clinically and radiographically for at least 10 months and had no evidence of carcinoma. Positive predictive values were positive, 100%; suspicious, 63%; atypical, 36%; benign, 0%. Most (40/43; 93%) carcinomas were invasive. In conclusion, ultrasound-guided FNA for nonpalpable breast lesions is highly accurate, and probabilistic reporting helps direct patient management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/dc.20068 | DOI Listing |
BMC Cancer
January 2025
Unité de Sénologie, Centre Jean PERRIN, Clermont-Ferrand, France.
Background: Most breast cancers are detected at an early stage in which case conservative surgery is indicated. An accurate preoperative localization technique is essential for conservative surgery of non-palpable breast lesions. Currently, the gold standard technique is wire localization (WL).
View Article and Find Full Text PDFSurgery
January 2025
Breast Surgery Unit, Veneto Institute of Oncology IOV, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy.
Background: Intraoperative ultrasound-guided breast-conserving surgery guarantees real-time direct visualization of tumor and resection margins. We compared surgical, oncologic, and cosmetic outcomes between intraoperative ultrasound-guided breast-conserving surgery and traditional (palpation- or wire-guided) surgery across all breast cancer lesion types.
Methods: This prospective observational cohort study was conducted at the Veneto Institute of Oncology between January 2021 and October 2022.
Phys Med Biol
January 2025
Department of Medical Physics, Jeroen Bosch Ziekenhuis, Henri Dunantstraat 1, 's-Hertogenbosch, 5223GZ, NETHERLANDS.
The treatment of breast cancer during pregnancy requires careful consideration of consequences for both maternal and fetal health. In non-pregnant patients, the use of radioactive iodine-125 (125I)-seeds is standard practice for localising non-palpable breast tumors before breast-conserving surgery. However, the use of 125I-seeds in pregnant patients has been avoided due to concerns about fetal radiation exposure.
View Article and Find Full Text PDFEur J Radiol Open
June 2025
Radiology Department, National Cancer Institute, Cairo University, Egypt.
Purpose: To investigate the impact of artificial intelligence (AI) reading digital mammograms in increasing the chance of detecting missed breast cancer, by studying the AI- flagged early morphology indictors, overlooked by the radiologist, and correlating them with the missed cancer pathology types.
Methods And Materials: Mammograms done in 2020-2023, presenting breast carcinomas (n = 1998), were analyzed in concordance with the prior one year's result (2019-2022) assumed negative or benign. Present mammograms reviewed for the descriptors: asymmetry, distortion, mass, and microcalcifications.
Clin Radiol
December 2024
Royal Liverpool University Hospital, Breast Radiology Unit, Liverpool, UK.
Aim: This study aimed to detail our experience of using SCOUT® radar reflector for lesion localisation in the breast and axilla.
Materials And Methods: This is a prospective cohort study describing our clinical experience with the first 500 patients who received SCOUT® to localise lesions in the breast and axilla (from 23 July 2020 to 4 April 2022). Study measures include patient demographics, lesion location, diagnostic pathways (screening or symptomatic), imaging, and surgical and pathology outcomes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!